



Ref: Syn/CS/SE/IP/2021-22/July/08

Syngene International Limited
Biocon SEZ, Biocon Park, Plot No. 2 & 3,
Bommasandra Industrial Area, IV Phase,
Jigani Link Road, Bengaluru 560099,
Karnataka, India.
T +91 80 6891 8000
F +91 80 6891 8808
CIN: L85110KA1993PLC014937
www.syngeneintl.com

July 20, 2021

To, The Manager, BSE Limited Corporate Relationship Department Dalal Street, Mumbai – 400 001	To, The Manager, National Stock Exchange of India Limited Corporate Communication Department Bandra (EAST), Mumbai – 400 051
Scrip Code: 539268	Scrip Symbol: SYNGENE

Dear Sir/Madam,

Sub: Investor Presentation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

With reference to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the Investor Presentation for the quarter ended June 30, 2021. The Company will use this presentation for any meeting scheduled with analysts or institutional investors up to September 30, 2021.

The above-mentioned Investor Presentation will also be available on website of the Company www.syngeneintl.com.

This is for your information and records.

Thanking You,

Yours faithfully,

For **SYNGENE INTERNATIONAL LIMITED**

Priyadarshini Mahapatra
Company Secretary and Compliance Officer

Enclosed: Investor Presentation.

Syngene

Putting Science to Work

Investor Presentation

July 2021

Quality
Confidentiality
Innovation
Science



Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking statements.

Important factors that could cause actual results to differ materially from our expectations include, amongst others general economic and business conditions in India, business outlook of our clientele and their research and development efforts our ability to successfully implement our strategy, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currencies, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition, changes in political conditions in India and changes in the foreign exchange control regulations in India.

Neither the company, nor its directors and any of the affiliates have any obligation to update or otherwise revise any statements reflecting circumstances arising after this date or to reflect the occurrence of underlying events, even if the underlying assumptions do not come to fruition.

Contents

1

Operating and Financial Highlights

2

Syngene – Putting Science to Work

3

Company and Business Overview

4

Financials

5

Shareholding and Share Information

Putting Science to Work

Contents

1

Operating and Financial Highlights

2

Syngene – Putting Science to Work

3

Company and Business Overview

4

Financials

5

Shareholding and Share Information

Putting Science to Work

Operating Highlights

- Growth was driven across all its business divisions as the Company continued to operate at normal levels
- Growth in the Dedicated R&D Center business is due in part to the expansion of the Bristol Myers Squibb R&D center.
- Revenue performance in the first quarter was also boosted by the manufacturing of remdesivir to fulfil high demand for the drug from Indian healthcare providers.
- Executed a five-year agreement with IAVI, to develop and manufacture three recombinant, monoclonal antibodies (mAbs) for HIV. The mAbs will be used for phase I and II human clinical studies
- Completed the second phase of expansion in Hyderabad and have close to 300 scientists working out of this facility

Q1 FY22 Financial Highlights

- Revenue from operations increased by 41% year-on-year
- EBITDA growth of 27% year-on-year
- PAT growth of 33% year-on-year

Total Revenue

Rs. 6,068 Mn

EBITDA

Rs. 1,773 Mn

Profit After Tax

Rs. 773 Mn

EBITDA Margin at 29%

PAT Margin at 13%

P&L Summary	Q1 FY22	Q1 FY21	YoY Change
Revenue from operations	5,945	4,216	41%
Total Revenue	6,068	4,369	39%
EBITDA	1,773	1,398	27%
<i>EBITDA Margin</i>	29%	32%	
PAT	773	580	33%
<i>PAT Margin</i>	13%	13%	

- Revenue from operations increased by 41% for the quarter compared to the previous year driven by steady performance across all four divisions and against a flat quarter last year. Accounting for the prior year effect, on a normalized basis, the year-on-year growth reflects a steady momentum during the quarter
- EBITDA margin for the quarter, was lower at 29% as compared to 32% in the previous year. The underlying EBITDA margin excluding other income and export incentives was lower by 170bps from 29.5% to 27.8% during the quarter. This was primarily driven by higher material cost mostly due to the high level of manufacturing activities
- Profit after tax was up 33% compared to previous year reflecting an overall strong performance for the quarter

Contributing through science

- Continued to manufacture Remdesivir for distribution in India and other countries under a voluntary license agreement with Gilead Inc.
- Established testing facility to conduct RT-PCR tests; tested close to 185,000 samples of which 90% were conducted free of cost to support employees and Bangalore community
- Scientists actively supporting clients in their COVID-19 vaccine research projects
- Continued to work on the coronavirus and have generated several variants of the SARS-CoV2 spike S1 protein to determine the efficacy of different vaccines to cross-protect people from these strains

Priorities: employee safety & business continuity



Safety and wellbeing of our people



Client projects on schedule



Resilient supply chain in place



Focus on operating efficiencies

- Rolled out a voluntary vaccination drive for our employees and their families and about 90% of them are now inoculated
- Maintained near normal levels of operations throughout the quarter, while keeping our staff safe and healthy by following all the COVID safety protocols that we had in place over the past 12 months

Contents

1

Operating and Financial Highlights

2

Syngene – Putting Science to Work

3

Company and Business Overview

4

Financials

5

Shareholding and Share Information

Putting Science to Work



Who we are and what we do

- Offering integrated research, development and manufacturing services to take projects from early discovery to commercial supply
- Working with clients from around the world to find solutions to their scientific challenges for small and large molecules while improving productivity, speeding up time to market and lowering cost of innovation
- Innovative culture driven by the expertise of a highly qualified team of 5,400+ employees and supported by state-of-the-art infrastructure and market-leading technology



400+ active clients



15 collaborations
with top 20 pharmaceutical
companies




450+ Patents
held with clients



2 Mn sq. ft.
of World class infrastructure,
qualified to meet international
standards



**4700+ talented team of
scientists**
Including ~490 PhDs



90% employees
in 25-40 year age
bracket



Rs. 22,489 Mn
Revenue for FY21



Rs. 3,821 Mn
PAT for FY21
before exceptional gain



Rs. 35,634 Mn
Capex Investment as on
March 2021



Integrated service provider offering **end-to-end** drug discovery, development and manufacturing services on a single platform



International accreditations

OHSAS 18001, GLP, cGMP, AAALAC & CPCSEA Certified Facilities, CAP accreditation, ISO/IEC 27001:2013 accreditation




25+ years of unparalleled experience



Flexible and varied business models

To meet client requirements




Experienced in successfully managing large relationships



Talented & experienced scientific and techno-commercial teams with significant management bandwidth

Our experience spans multiple industry segments and partnerships with global leaders across the world



Contents

1

Operating and Financial Highlights

2

Syngene – Putting Science to Work

3

Company and Business Overview

4

Financials

5

Shareholding and Share Information

Putting Science to Work

- **Biocon Limited**, founded in 1978, is an innovation-led global biopharmaceuticals company
- **Syngene**, a subsidiary of Biocon Limited, was established in 1993 as India's first Contract Research Organization - Company has 25 years plus of unparalleled experience in novel molecule discovery, development and manufacturing services
- **Biocon Biologics**, another subsidiary of Biocon Limited, consolidates the development, manufacturing and commercialization operations of Biocon's biosimilars business

Integrated services:

- Discovery
- Development
- Manufacturing sml/lg mol.s

Syngene

Biocon

**Biocon
Biologics**

- Product Based
- Biosimilars
- Formulations and Compounds
- Alternative Therapeutic Drugs



A Global CRO

- Integrated Drug Discovery, Development and Manufacturing service provider
- Small and large molecules, ADCs, oligonucleotides, PROTACs
- Listed on Indian Stock Exchanges (NSE and BSE)

Values

- **Integrity:** To be ethical, honest and transparent in all we do
- **Excellence:** To commit ourselves to the highest levels of scientific and operational excellence
- **Professionalism:** To practice the highest degree of professionalism by fostering individual accountability, reliability, continuous improvement and customer focus



Our Vision

To be a world class partner delivering innovative scientific solutions

Quality Focus

- Quality driven organization
- Excellent track record of compliance with global regulators
- US FDA, EMA and PMDA approved, GLP, GMP Certified, AAALAC Accredited facility
- Over 15 regulatory and 244 client audits in the last 3 years

Track Record

- Collaborations and partnerships to deliver numerous clinical candidates
- Delivery history for integrated CMC programs towards FIH and beyond

IP Position

- IP assigned to clients
- Strong track record of data integrity and security

Foundation

- Operations started
- Expansion of R&D Lab
- Granted 100% EOU status by the Government of India

Globalization and strategic collaboration

- Expanded into formulations development
- Contract with Endo Pharmaceuticals to develop novel anti cancer biological therapeutic molecules
- Collaboration with Baxter to set up a dedicated R&D center
- Extension of collaboration with BMS; Merger of Clinigene
- Crossed annual turnover of Rs. 5,000 Mn

Consolidation and growth

- Crossed annual turnover of Rs. 20,000 Mn in 2020
- Expanded collaboration with BMS until 2030; Baxter until 2024
- Expansion in Mangalore for commercial API mfg.
- Expansion in Biologics manufacturing facilities with microbial capabilities
- Laboratory capacity expansion in Hyderabad
- Expansion of IDD platform with 3DC collaboration

1993 -
2000

2001 -
2009

2010 -
2014

2015 -
2018


2019 -
2021

Expansion

- Expanded service offerings to include chemical development, safety assessment, biologics development
- Collaboration with BMS to set up BBRC, Syngene's first dedicated R&D Center
- Crossed annual turnover of Rs. 1,000 Mn

IPO and further collaborations

- IPO and listing
- Collaboration with Amgen and Herbalife to set up dedicated R&D centers



Assets

- Solid foundations based on extensive laboratory infrastructure, technology investments, skilled workforce, strong leadership, and financial strength

Services

- Deploying asset base to offer integrated services across scientific discovery, development and manufacturing tailored to the requirements of every project

Value we create



- Creating value for clients by delivering innovation while providing both time and cost-to-market benefits. Business activities also enable value creation for our employees, shareholders and the community at large

Reinvestment

- Continued investment in additional capacity and new technology to maintain pace as science evolves

All figures in Rs. Mn unless otherwise specified




- Growth driven by increase in sales from existing clients and acquisition of new clients
- Strategy to extend client relationship over a longer period of time, with continuous focus on client satisfaction
 - Growth in total number of clients
 - Increase in average revenue from largest clients
 - Increase in number of services offered to clients



Total Revenue (Rs. Mn)

EBITDA (Rs. Mn)

Profit After Tax * (Rs. Mn)



Expand/Extend Existing Clients

- High service integration
- Dedicated centers model

Engage New Clients

- Tailored service offerings and dedicated personnel

Moving from CRO to CRAMS with commercial manufacturing


- "Follow the molecule" by expanding into commercialisation

Capacity Expansion

- Consistent investment
- FTE services, manufacturing, formulation, biologics, stability

Capability Additions

- New capabilities across multiple domains incl. the allied sectors
- Stability, analytical and bio-analytical services, viral testing, Oligonucleotide bioinformatics
- New platforms: siRNA, ADC, CAR-T, PROTACs



Discovery Services

Engaged in early-stage research, from target identification to delivery of drug candidates for further development

Capabilities include Chemistry, Biology, Safety Assessment, and Research Informatics for small molecules; recombinant DNA engineering, cell line development, Next Generation Sequencing, and protein sciences for large molecules

Development Services

Engaged in activities from pre-clinical to clinical trials, including drug substance and drug product development, and associated services to demonstrate the safety, tolerability, and efficacy of the selected drug candidate, cGMP compliant manufacturing of clinical supplies, and registration batches for small molecules

Manufacturing Services

Engaged in the manufacturing of small and large molecules for commercial supplies through cGMP-compliant facilities, a state-of-the art API manufacturing campus and a biologics manufacturing facility

Dedicated R&D Centers

Dedicated R&D facilities for strategic clients providing exclusive access to research teams, infrastructure, and project management to support the client's R&D requirements.



Dedicated R&D Labs

- Dedicated scientific and support teams work exclusively on the client's project
- Clients are provided with customized and ringfenced infrastructure
- Long-term strategic alliances that last usually five years or more



FTE

- Pre-defined numbers of scientific personnel from pre-determined disciplines work full-time on client projects
- Deliverables and team composition evolve as the project advances
- Agreements are typically renewed annually



FFS

- Client collaboration to deliver agreed services within a defined scope.
- Flexible, on demand personnel and research infrastructure deployed to achieve the project objectives
- Engagements may be short or long-term



Risk-reward

- Across a portfolio of stage gate-driven research projects
- Client benefits from reduced upfront payments in exchange for significant success-based milestone payments against pre agreed criteria

... and are open to any single or combination of above

Our dedicated R&D centers exemplify the success of our long-term strategic alliances



300,000+ sq. ft. laboratory space

Largest R&D Center in Asia for BMS (est.d 2009). Contract till 2030

Integrated drug discovery and development in multiple therapeutic areas, including cardiovascular, fibrosis, immunology, oncology, translational medicine and pharmaceutical development

Produced >10 drug candidates for further study and advanced new compounds for first-in-human studies



70,000 sq. ft. laboratory space

Dedicated R&D Center in India for Baxter (est.d 2013). Contract till 2024

R&D activities centred on product and analytical development, preclinical evaluation in parenteral nutrition and renal therapy

Collaboration expanded to include microbiology research and preclinical assessment projects for medical devices

Delivered four new product development projects for registration in the US and European Union markets.



60,000 sq. ft. laboratory space

Exclusive R&D Center for Amgen Inc. in India (est.d 2016)

Focus on medicinal & process chemistry, biologics, bioprocess, drug metabolism, pharmacokinetics, bioanalytical research and pharmaceutical development

Operational excellence initiatives were introduced to improve productivity across functional areas.




3,200 sq. ft. laboratory space

Herbalife's 1st Nutrition Research and Development Lab in India (est.d 2016)


Dedicated Center houses cGMP formulation lab to support product testing, sampling and end-product development

Focus on product development, sensory evaluation and testing, scientific content writing, project management, formulation development, analytical service, stability study, other related services

Our end-to-end platform enables us to be a 'one-stop-shop' for discovery, development and manufacturing (small and large molecules)



Discovery	Development	Manufacturing
Chemistry	Drug Substance	Clinical Supplies
Biology	Drug Product	
	Integrated Drug Substance – Drug Product	HPAPI
Safety Assessment		Specialty Molecules
Integrated Drug Discovery	Human Pharmacology Unit (Phase 1)	Commercial Supplies
Therapeutic Antibody Discovery and Engineering; Cell Line Development	Bio Analytical Lab (Large Molecules)	
	Stability Services	
Bioprocess Development, Process Characterisation, Clinical Manufacturing (Microbial and Mammalian)		
Research Informatics: Bioinformatics, integrative analysis, target dossiers, systems modeling, cheminformatics and AI		



- Interdisciplinary activities: Integrated approach
- Comprise of Chemistry, Biology, Toxicology and Bioinformatics services for both small and large molecules
- Client deliverables can be a compound(s), process(es) or a report
- Primarily FTE engagements with high renewability



- Encompass activities across multiple disciplines as a molecule moves from pre-clinical to clinical trials
- Key activities include:
 - Drug substance development (process R&D and optimisation)
 - Drug product development (pre-formulation and formulation development)
 - Allied services (stability services, viral testing, bioanalytical)
- Primarily FFS engagements which increase in volume/scale over time

Small Molecules



- State-of-the-art cGMP (Current Good Manufacturing Practices) and GMP (Good Manufacturing Practice) facility to manufacture new chemical entities (NCEs)
- Designed to support multi gram to 100s of kgs/ batch of Intermediates and APIs for clinical trials
- New greenfield investments in Mangalore to support larger commercial scale requirements



Syngene's API manufacturing facility at Mangalore

Biologics



- Mammalian and microbial capabilities
- Can support early stage, late stage and commercial launch supply requirements in mammalian
- Capacities to support large volumes for late stage clinical requirements



Syngene's USFDA approved manufacturing facility at Bangalore

HQ Campus – 90 Acres in Bangalore where most of Syngene's capabilities are housed today



Biologics Expansion: HQ Campus Biologics Manufacturing Plant
Scale: Mammalian- ~100-2000L
Microbial – ~200-500L

R&D Expansion: Genome Valley, Hyderabad, India commenced operation in Aug 2019



API Mfg Expansion: Commercial Manufacturing to support product launch in Mangalore, India - Commenced operation in March 2020; Capacity: ~70KL ; Reactor size: 2-12KL

Agile and experienced workforce supported by our commitment to continuous learning

~5,400
strong pool of employees

Environment that engages our employees and enables them to grow

24*%

female employees vs 16% in FY16



Adapting to the new normal

- 90% of the workforce back on site before the end of Q1, while remaining 10%, who have non-site-dependent roles, continued to work remotely due to stringent COVID-19 safety protocols in place
- L&D initiatives during the lockdown included training programs for building technical, leadership, and behavioural skills



Enriching talent pool

- Started Syngene Training Academy (STA) to make the transition smoother for new campus hires and equip them with essential skills



Fostering inclusion and diversity

- Equal opportunity employer, proactively promoting inclusion and diversity across our workforce to get the best talent mix



Encouraging development of life skills and technical expertise

- Internally developed training modules tailored to our business and the specific needs of our employees




Healthy Work Environment Certified as 'Great Place to Work'


- Ratification of Syngene's cohesive and healthy work environment that focuses on collaboration, nurturing talent and encouraging innovation

4700+ scientists delivering quality output and creating competitive edge

■ PhDs ■ Master's Degree ■ Others



Generating reliable and retrievable data by using advanced technology platforms.



Certification as per ISO 13485:2016, ISO/IEC 27001 and ISO 9001:2015 requirements

Our dedicated Strategic Sourcing professionals have the expertise and experience to work closely with our global supplier base to ensure timely delivery of supplies for smooth operations of the company, while ensuring strict adherence to quality and regulatory compliances



Procurement transformation

- Optimized demand forecasting, ordering and delivery on a just-in-time basis
- Building deep understanding of products markets and suppliers to obtain optimum pricing
- Improving speed of order processing and turnaround times



Digitalization


Increased transparency, efficiency, and traceability in the procurement lifecycle with process automation



AI based automation


- Started the implementation of AI-enabled robotic process automation (RPA), covering both GMP and non-GMP materials and services.

Maintaining strong resilience during pandemic



Build capability	Black belt Certification 29 Nos
Create culture of excellence (Function wise)	Green Belt Certification 188 Nos
	White Belt Certification 4698 Nos
Centralized project life cycle (Dashboard & MIS)	Kaizens 2135 Nos
	OU metrics dashboard
	Balanced score card

- Syngene rolled out the **SQDECC*** continuous improvement program organization-wide to engage all employees to improve operational efficiency and effectiveness metrics
- **96 Lean daily management** boards across organization focusing on world class practices and continuous improvement



Led by a globally experienced management team

Management team



Jonathan Hunt
Managing Director and
Chief Executive officer



Dr. Mahesh Bhargat
Chief Operating Officer



Sibaji Biswas
Chief Financial Officer



Ashu Tandon
Chief Commercial Officer



Beena Govindaraju
VP Corporate Affairs

Previous experience

AstraZeneca

Sanofi, Amgen,
Monsanto

Vodafone,
Hutchison Telecomm

IQVIA
Accenture

ABB, SAP,
Dell EMC, Logica

Management team



Alok Mehrotra
Chief Quality Officer



Sanjeev Sukumaran
Chief Human Resources officer



Dr. Kenneth Barr
SVP Discovery Services



Dr. Jan-Olav Henck
SVP Development Services

Previous experience

Reckitt Benckiser,
PepsiCo, Godrej, DRL

Thomson Reuters

FORMA
Merck

Bayer AG,
SSCI, Aptuit

Advised by visionary Board of Directors



Kiran Mazumdar Shaw
Non-Executive Chairperson

Chairperson of Biocon Limited, ~45 years of experience in the field of biotechnology



Jonathan Hunt
Managing Director and Chief Executive officer

~30 years of experience in the global biopharmaceuticals industry



Dr. Carl Diccio
Independent Director

Chief Scientific Officer in Foghorn Therapeutics



Professor Catherine Rosenberg
Non-Executive Director

Professor in electrical and computer engineering at the University of Waterloo, Canada



Vinita Bali
Independent Director

Chief Executive Officer & MD of Britannia Industries from 2005 to 2014



John Shaw
Non-Executive Director

Non-Executive Vice-Chairman of Biocon Limited



Paul Blackburn
Independent Director

40 years+ experience in the field of finance



Sharmila Abhay Karve
Independent Director

Retired as audit partner from Price Waterhouse



Dr Vijay Kuchroo
Independent Director

Founded five biotech companies including CoStim Pharmaceuticals and Tempero Pharmaceuticals



Kush Parmar
Independent Director

Managing Partner at 5AM Ventures, a life sciences venture capital firm

Safety is at the heart of everything we do



Accredited with ISO 45001:2018 for its Occupational Health and Safety (OH&S) measures

100%

Lab Hazard Analysis training delivered to all employees working in laboratories
12 million manhours without Lost Time Incident (LTI) on rolling 12-month

27,000 hrs

Regular safety training under **Kavach, our flagship safety program** considerable improvement across several safety metrics

Increased incident reporting

Reduction of incidents

Improved risk control measures

Improved general safety perception



Awarded **'Safe Workplace Champion Award'** at the 8th Manufacturing Supply Chain Summit and Awards

Committed to environmental protection



Accredited with ISO 14001:2015 for its effective Environment Management System (EMS)

21,291 KL

of water conserved through effective rainwater harvesting as well as recycling of used water

888 MT

of waste disposed in an environment-friendly manner and ~287 MT of solid waste recycled in FY20

3-R's

Operations constantly monitored to identify opportunities to reduce, reuse, and recycle waste

53,278

tonnes

of carbon dioxide emissions reduced in FY21

62.6Mn

KWH

of electricity usage through Green energy sources

82%

of Energy consumption is through green energy sources

We have consistently received industry recognition for our scientific capability and best practices

- **Dynamic Enterprise of the Year 2016** - At the 9th Annual Pharmaceutical Leadership Summit & Pharma Leaders Business Leadership Awards 2016- in recognition for its contribution to the field of Research and Development for the Life Science Industry
- **CII Award** - Won first place in the Office/Software/Service Sector
- **CII Award** - Four Star Rating on Environment Health & Safety Management System

- **Bio-Excellence Award 2018** - At Bengaluru Tech Summit, Bengaluru
- **Best Bioprocessing Excellence Award 2018** - At 5th Biologics Manufacturing Asia, Singapore
- **Healthcare Company of the Year 2018** - At the 7th Annual VC Circle Awards 2018, Mumbai
- **HR Excellence Award 2018 'For Best Talent Management Strategy'** - World HRD Congress, Mumbai

- **CMO Leadership Award Winner 2020** - under Categories: Capabilities, Compatibility, Expertise and Service
- Bioprocessing Excellence Awards 2020 in the category 'Bioprocessing Excellence in South Asia—Viral Clearance and Safety Testing'
- **Great Place to Work Certified™ Company** (ASSOCHAM) CSR & NGO Awards 2020 for our contribution to COVID-19 relief work in Karnataka.



2016

2017

2018

2019

2020


2021

- **Best Contract Research Organization (CRO) Provider - Runner-up Award** - At The 4th Annual World ADC Awards 2017
- **Bio Services Excellence Award 2017** - Bangalore Tech Summit

- Ranked as one of the **25 fastest growing companies in India** by Outlook Business
- **CMO Leadership Awards 2019** - Presented by Life Science Leader Magazine
- **FICCI CSR Award for Environmental Sustainability** -At the 17th Edition of the awards in New Delhi
- **Safe Workplace Champion Award** - At the 8th Manufacturing Supply Chain Summit and Awards
- **Best Leadership Development Program for Middle Management Award** - At the 6th Global Training and Development Leadership Awards
- **India Pharma Award 2019** - For "Excellence in Contract Research and Manufacturing Services" at CPhI & P-MEC India Expo.
- **Utthama Suraksha Puraskar 2019** - (Pharma and Chemical Manufacturing Category) by National Safety Council of India (NSCI). Leadership Awards

- **Dream Companies to Work Award** at the 29th Edition of the World HRD Congress Awards.

Syngene has a risk management framework to identify, monitor, report and manage risk across the business. Every risk owner monitors and manages risks relevant to their area of responsibility.



Contents

1

Operating and Financial Highlights

2

Syngene – Putting Science to Work

3

Company and Business Overview

4

Financials

5

Shareholding and Share Information

Putting Science to Work

Particulars	Q1 FY22	Q1 FY21	YoY Change	Q4 FY21	QoQ change
Revenue from operations	5,945	4,216	41%	6,586	(10%)
Other Income	123	153	(20%)	184	(33%)
Total Revenue	6,068	4,369	39%	6,770	(10%)
Material and Power Costs	2,082	1,019	104%	1,762	18%
Employee Costs	1,711	1,404	22%	1,826	(6%)
Foreign exchange (gain)/loss, net	(154)	33	(567%)	(47)	228%
Other Expenses	656	515	27%	891	(26%)
EBITDA	1,773	1,398	27%	2,338	(24%)
EBITDA Margin	29%	32%		34%	
Underlying EBITDA Margin[^]	28%	30%		33%	
Depreciation, Interest & Tax	1,000	818	22%	960	4%
PAT (before exceptional gain)	773	580	33%	1,378	(44%)
PAT Margin	13%	13%		20%	
PAT (after exceptional gain)	773	580	33%	1,606	(52%)

Particulars	FY21	FY20	YoY Change
Revenue from operations (excl export incentives)	21,802	19,465	12%
Export incentives	41	654	(94%)
Other Income	646	816	(21%)
Total Revenue	22,489	20,935	7%
Material and power costs	5,839	5,652	3%
Employee costs	6,602	5,804	14%
Foreign exchange (gain)/loss, net	(171)	(144)	19%
Other Expenses	2,855	2,628	9%
EBITDA	7,364	6,995	5%
EBITDA Margin (%)	32.7%	33.4%	
Underlying Margin (%)	30.6%	28.4%	
Depreciation, Interest and tax	3,543	3,333	6%
Profit After Tax before exceptional gain	3,821	3,662	4%
PAT Margin (%)	17.0%	17.5%	
Exceptional gain relating to Insurance Claim	228	459	(50%)
Profit After Tax after exceptional gain	4,049	4,121	(2%)

Balance Sheet Highlights

As on 31st March 2021

Shareholders' funds	28,214
Net Fixed assets	24,382
Other net assets ⁽¹⁾	(2,643)
Net cash/(debt) ⁽²⁾	6,475
Total Use of Funds	28,214

Contents

1

Operating and Financial Highlights

2

Syngene – Putting Science to Work

3

Company and Business Overview

4


Financials

5

Shareholding and Share Information

Putting Science to Work

Syngene's Shareholding Pattern*



Syngene's Share Information*

NSE Ticker	SYNGENE
BSE Ticker	539268
Market Cap (Rs. Mn)	2,33,785
% free-float	29%
Free-float market cap (Rs. Mn)	67,003
Share Outstanding (Mn)	401
3M ADTV ^ (Shares)	439,368
3M ADTV ^ (Rs. Mn)	255

THANK YOU

www.syngeneintl.com

Putting Science to Work

For more details

- Visit www.syngeneintl.com
- IR Contact:
Krishnan G
+ 91 806 891 9807
investor@syngeneintl.com